Janine Midori Figueiredo Watanabe

Janine Midori Figueiredo Watanabe

Auto-generated profile, based on publicly available information

Janine Midori Figueiredo Watanabe

Department of Medicine, State University of Piauí, Teresina, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
EPEric Pasqualotto
Eric Pasqualotto
JWJanine Midori Figueiredo Watanabe
Janine Midori Figueiredo Watanabe
DGDouglas Mesadri Gewehr
Douglas Mesadri Gewehr
RMRaphaela da Silva Maintinguer
Raphaela da Silva Maintinguer
SSSimone van de Sande‐Lee
Simone van de Sande‐Lee
CPCarlos Eduardo Andrade Pinheiro
Carlos Eduardo Andrade Pinheiro

13 September 2024 in Metabolism Open
Verified
Journal Article
Open access
EPEric Pasqualotto
Eric Pasqualotto
RFRafael Oliva Morgado Ferreira
Rafael Oliva Morgado Ferreira
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
AHAlexandre Hohl
Alexandre Hohl
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
SSSimone van de Sande-Lee
Simone van de Sande-Lee
To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D). PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched for placebo-controlled, randomized clinical trials (RCTs) published up until February 23, 2024. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) for binary endpoints were computed, with 95 % confidence intervals (CIs). A total of three studies were included, comprising 640 patients, of whom 510 were prescribed retatrutide. Compared with placebo, retatrutide significantly reduced body weight (WMD -10.66 kg; 95 % CI -17.63, −3.69), body mass index (WMD -4.53 kg/m2; 95 % CI -7.51, −1.55), and waist circumference (WMD -6.61 cm; 95 % CI -13.17, −0.05). In addition, retatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥5 % (RR 2.92; 95 % CI 2.17–3.93), ≥10 % (RR 9.32; 95 % CI 4.56–19.06), ≥15 % (RR 18.40; 95 % CI 6.00–56.42), and ≥20 % (RR 16.61; 95 % CI 4.17–66.12). In this meta-analysis, the use of once-weekly subcutaneous retatrutide was associated with a significant reduction in body weight and improvement of metabolic markers in patients with overweight, obesity and/or T2D, compared with placebo, with an increase in non-severe gastrointestinal and hypersensitivity adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-weekly subcutaneous retatrutide over the long term.

11 April 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
RFRafael Oliva Morgado Ferreira
Rafael Oliva Morgado Ferreira
TTTalita Trevisan
Talita Trevisan
EPEric Pasqualotto
Eric Pasqualotto
PSPedro Schmidt
Pedro Schmidt
MCMatheus Pedrotti Chavez
Matheus Pedrotti Chavez
SSSimone van de Sande-Lee
Simone van de Sande-Lee
The aim of this study was to assess the efficacy and safety of hybrid closed-loop (HCL) systems for insulin delivery in children and adolescents with type 1 diabetes (T1D). We searched Embase, PubMed, and Cochrane Library for randomized controlled trials (RCTs) published until March 2023 comparing the HCL therapy with control therapies for children and adolescents with T1D. We computed weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) with 95% confidence intervals (CIs) for binary endpoints. [...] ABSTRACT The aim of this study was to assess the efficacy and safety of hybrid closed-loop (HCL) systems for insulin delivery in children and adolescents with type 1 diabetes (T1D). We searched Embase, PubMed, and Cochrane Library for randomized controlled trials (RCTs) published until March 2023 comparing the HCL therapy with control therapies for children and adolescents with T1D. We computed weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) with 95% confidence intervals (CIs) for binary endpoints.